The Lancet Gastroenterology & Hepatology is a monthly journal that considers original research, reviews, and personal views in gastroenterology and hepatology from around the world. In the monthly podcasts, editors of the journal discuss highlights of the current issue.
…
continue reading
Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgica ...
…
continue reading
1
In conversation with... Cathy Lu
11:15
11:15
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
11:15
Cathy Lu (University of Calgary) discusses a consensus statement on the use of intestinal ultrasound for assessing and monitoring small bowel strictures in Crohn's disease.Kirjoittanut The Lancet
…
continue reading
1
Cathy Lu on intestinal ultrasound for assessing and monitoring Crohn's disease small bowel strictures
11:15
11:15
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
11:15
Cathy Lu (University of Calgary) discusses a consensus statement on the use of intestinal ultrasound for assessing and monitoring small bowel strictures in Crohn's disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00265-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation…
…
continue reading
1
Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis
14:42
14:42
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:42
Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00200-0?dgcid=buzzsprout_icw_podcast_generic_langas Continue this co…
…
continue reading
1
In conversation with... Peter De Cruz
14:42
14:42
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:42
Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.Kirjoittanut The Lancet
…
continue reading
1
Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease
34:15
34:15
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
34:15
Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease. Read the full articles: https://www.thelancet.com/journals/…
…
continue reading
1
In conversation with... Shahida Din and Beatriz Gros
34:15
34:15
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
34:15
Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.Kirjoittanut The Lancet
…
continue reading
1
In conversation with... Arndt Vogel
18:31
18:31
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
18:31
Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.Kirjoittanut The Lancet
…
continue reading
1
Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer
18:23
18:23
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
18:23
Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgc…
…
continue reading
1
In conversation with... Nancy Baxter
25:05
25:05
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
25:05
Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.Kirjoittanut The Lancet
…
continue reading
1
Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy
25:05
25:05
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
25:05
Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00084-0?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversatio…
…
continue reading
1
In conversation with... Sanna Nybacka and Magnus Simrén
23:16
23:16
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
23:16
Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.Kirjoittanut The Lancet
…
continue reading
1
Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS
23:16
23:16
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
23:16
Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00045-1/fulltext?dgcid=buzzsprout_tlv_podcast_generic_langas …
…
continue reading
1
In conversation with... Nuru Noor
19:55
19:55
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
19:55
Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.Kirjoittanut The Lancet
…
continue reading
1
Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease
19:55
19:55
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
19:55
Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Foll…
…
continue reading
1
In conversation with... Yusuke Shimakawa
20:54
20:54
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
20:54
Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Kirjoittanut The Lancet
…
continue reading
1
Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa
20:54
20:54
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
20:54
Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00449-1?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... http…
…
continue reading
1
Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake
16:39
16:39
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
16:39
Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00443-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this convers…
…
continue reading
1
In conversation with... Mads Israelsen
16:39
16:39
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
16:39
Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.Kirjoittanut The Lancet
…
continue reading
1
Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity
23:19
23:19
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
23:19
Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00317-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on socia…
…
continue reading
1
In conversation with... Louise Dye
23:19
23:19
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
23:19
Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity.Kirjoittanut The Lancet
…
continue reading
1
In conversation with... Tzu-Chan Hong
14:40
14:40
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:40
Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region.Kirjoittanut The Lancet
…
continue reading
1
Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region
14:40
14:40
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:40
Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00281-9/fulltext?dgcid=buzzsprout_icw_podcast_gen…
…
continue reading
1
Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy
14:45
14:45
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:45
Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00228-5/fulltext?dgcid=…
…
continue reading
1
In conversation with... Sarah Moen
14:45
14:45
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:45
Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants.Kirjoittanut The Lancet
…
continue reading
1
In conversation with... Anna Emilie Kann
16:19
16:19
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
16:19
Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease.Kirjoittanut The Lancet
…
continue reading
1
Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease
16:19
16:19
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
16:19
Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00192-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue t…
…
continue reading
1
Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction
16:31
16:31
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
16:31
Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00191-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversati…
…
continue reading
1
In conversation with... Robert Krouse
16:31
16:31
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
16:31
Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.Kirjoittanut The Lancet
…
continue reading
1
Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis
14:29
14:29
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:29
Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases. Read the full article: https://www.thelancet.com/journals/langas/art…
…
continue reading
1
In conversation with... Marc Rothenberg
14:29
14:29
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:29
Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.Kirjoittanut The Lancet
…
continue reading
1
In conversation with... Michael Pavlides
17:41
17:41
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
17:41
Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.Kirjoittanut The Lancet
…
continue reading
1
Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease
17:41
17:41
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
17:41
Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00017-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this c…
…
continue reading
1
Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis
12:48
12:48
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
12:48
Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis. Read the full article: https://www.…
…
continue reading
1
In conversation with... Jasmohan Bajaj
12:48
12:48
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
12:48
Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.…
…
continue reading
1
In conversation with... Adelina Artenie
17:15
17:15
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
17:15
Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender.Kirjoittanut The Lancet
…
continue reading
1
Adelina Artenie on the incidence of HIV and HCV in people who inject drugs
17:15
17:15
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
17:15
Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00018-3/fulltext?dgcid=buzzsprout_icw_podcast_langas_…
…
continue reading
1
In conversation with... Johan Burisch
20:00
20:00
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
20:00
Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.Kirjoittanut The Lancet
…
continue reading
1
Johan Burisch on the costs of inflammatory bowel disease in high-income settings
20:00
20:00
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
20:00
Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings. Read the Commission here: The cost of inflammatory bowel disease in high-income settings Continue this conversation on social! Fo…
…
continue reading
1
In conversation with... Edouard Louis
21:30
21:30
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
21:30
Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.Kirjoittanut The Lancet
…
continue reading
1
Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease
21:30
21:30
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
21:30
Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease. Read the full article: Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE) Continue…
…
continue reading
1
In conversation with... Paula Ghaneh
20:20
20:20
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
20:20
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma.Kirjoittanut The Lancet
…
continue reading
1
Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer
20:20
20:20
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
20:20
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma. Read the full article: Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINO…
…
continue reading
1
In conversation with... Dan Turner
14:51
14:51
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:51
Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.Kirjoittanut The Lancet
…
continue reading
1
Dan Turner on vedolizumab in children with IBD
14:51
14:51
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
14:51
Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD. Read the full article: Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS) Continue this conversation on social! Follow us today at... https:…
…
continue reading
1
In conversation with... Simon Baunwall
15:21
15:21
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
15:21
Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.Kirjoittanut The Lancet
…
continue reading
1
Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection
15:21
15:21
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
15:21
Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection. Read the full article: Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT) Continue this conversa…
…
continue reading
1
In conversation with... James Alexander
13:48
13:48
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
13:48
James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.Kirjoittanut The Lancet
…
continue reading
1
James Alexander on immune responses to COVID-19 vaccination in patients with IBD
13:48
13:48
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
13:48
James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease. Read the full article: COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory b…
…
continue reading
1
Filip Knop on liraglutide for bile acid diarrhoea
15:02
15:02
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
15:02
Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.Kirjoittanut The Lancet
…
continue reading
1
Filip Knop on liraglutide for bile acid diarrhoea
15:02
15:02
Toista myöhemmin
Toista myöhemmin
Listat
Tykkää
Tykätty
15:02
Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea. Read the full article: Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial Continue this convers…
…
continue reading